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ABSTRACT  
Mitochondria are the principal destination for labile iron (LI), making these organelles particularly 
susceptible to oxidative damage upon exposure to ultraviolet A (UVA, 320-400 nm), the 
oxidizing component of sunlight. The LI-mediated oxidative damage caused by UVA to 
mitochondria leads to necrotic cell death via ATP depletion. Therefore targeted removal of 
mitochondrial LI via highly specific tools from these organelles may be an effective approach to 
protect the skin cells against the harmful effects of UVA. In this work, we designed a 
mitochondria-targeted hexadentate (tricatechol-based) iron chelator linked to mitochondria- 
homing SS-like peptides. The photoprotective potential of this compound against UVA-induced 
oxidative damage and cell death was evaluated in cultured primary skin fibroblasts. Our results 
show that this compound provides unprecedented protection against UVA-induced 
mitochondrial damage, ATP depletion and the ensuing necrotic cell death in skin fibroblasts and 
this effect is fully related to its potent iron-chelating property in the organelle. This mitochondria-
targeted iron chelator has therefore promising potential for skin photoprotection against the 
deleterious effects of UVA component of sunlight. 
 
Key words: labile iron - iron chelator - mitochondria - oxidative stress - UVA - photoprotection – 
skin – fibroblasts - ROS 
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INTRODUCTION 
The ultraviolet A (UVA, 320-400 nm) component of sunlight is weakly absorbed by most 
biomolecules but is predominantly oxidative in nature, generating reactive oxygen species 
(ROS) via photochemical interactions involving non-DNA cellular chromophores (Tyrrell, 1996). 
In addition, the presence of a cellular pool of iron bound to small ligands, called labile iron pool 
(LIP), sensitizes cells to UVA as it can catalyse the formation of toxic oxygen-containing radicals 
(Hider and Kong, 2013; Cabantchik, 2014) such as hydroxyl radical (•OH) via Fenton chemistry 
(Winterbourn, 2008). This can ultimately overwhelm the cellular antioxidant defense 
mechanisms and lead to cell damage and death (Reelfs et al., 2004; Reelfs et al., 2010; Ma et 
al., 2015).  
Originally, LIP was considered to be cytosolic, however recent studies have indicated that only a 
small proportion of the intracellular redox-active pool of LI resides in the cytosol (Aroun et al., 
2012; Ma et al., 2015). Indeed due to constant need for LI in various cellular functions, cytosolic 
LIP is usually rapidly relocated to distinct subcellular compartments, notably lysosomes and 
mitochondria, which are the dominant sites for iron redistribution as well as iron sequestration 
and incorporation into proteins (Reelfs et al., 2010; Sohn et al., 2008; Levi and Rovida, 2009; 
Fakih et al., 2008). Mitochondria require a continuous provision of LI from the cytosol as they 
are the main site for heme and iron–sulfur cluster synthesis which are then exported to other 
cell compartments (Hider and Kong, 2013). Several mechanisms appear to account for 
mitochondrial iron uptake. In addition, mitoferrins 1 and 2 have been involved in iron transport to 
mitochondria in a range of organisms (Paradkar et al., 2009; Shaw et al., 2006). As a result of 
iron influx, the concentration of LI in the mitochondrial matrix exceeds significantly that of 
cytosol (Petrat et al., 2001; Petrat et al., 2002), which make these organelles highly susceptible 
to oxidative damage. Consequently, since mitochondria are the major sites of oxygen 
consumption and LI is also a strong catalyst of harmful ROS formation, the simultaneous 
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presence of oxygen and iron appears to be detrimental to the organelles (Levi and Rovida, 
2009). Excessive mitochondria-mediated ROS production can promote oxidative damage to 
mitochondrial components, impeding key mitochondrial functions, notably ATP synthesis, heme 
synthesis and iron sulfur cluster assembly (Murphy, 2009; Aroun et al., 2012). Oxidative 
damage to mitochondria will also permeabilize mitochondrial outer membrane resulting in the 
leakage to the cytosol of cytochrome c (cyt c). This will activate the cell's apoptotic or necrotic 
pathway, depending on the extent of the oxidizing insult (Pourzand and Tyrrell, 1999; Shidoji et 
al., 1999). In the event of severe oxidative damage to mitochondrial membranes, ATP depletion 
will lead to cell death via necrosis because apoptosis involves energy-requiring steps, especially 
in the formation of the apoptosome complex between apoptosis protease activating factor -1 
(Apaf-1)  and cyt c (Zou et al., 1999; Leist et al., 1997; Li et al., 1997; Green and Reed, 1998).  
Mitochondria are endowed with protective mechanisms against iron-catalyzed ROS-induced 
damage. Nevertheless, these organelles remain highly sensitive to oxidative damage as 
deregulation in mitochondrial iron homeostasis has been linked to the development of 
pathological conditions and cell death (Levi and Rovida, 2009; Kakhlon et al., 2010). In this 
context, we have shown that UVA radiation or H2O2 treatment of human skin fibroblasts and 
Jurkat T leukemia cell line in culture leads to both immediate oxidative damage to mitochondrial 
membrane and a concomitant rise in the cytosolic LIP (Zhong et al., 2004; Yiakouvaki et al., 
2006; Al-Qenaei et al., 2014). As a result of mitochondrial membrane damage, the electron 
chain reactions are disrupted leading to the excessive generation of ROS and mitochondrial 
ATP depletion that ultimately causes necrotic cell death. Additionally, it has been shown that 
both UVA and H2O2 induce oxidative damage to mitochondrial DNA, with potential implication in 
photoaging, and skin cancer (Berneburg et al., 1999; Krishnan and Birch-Machin, 2005; 
Oyewole et al., 2014). 
Because mitochondria are a major source of ROS, much effort has been focussed on the 
design of mitochondria-targeted antioxidant compounds such as MitoQ, a ubiquinone derivative 
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conjugated to triphenylphosphonium that enables this molecule to enter the mitochondria 
(James et al., 2007). An unrelated compound, 4,5-dihydroxy-1,3-benzenedisulfonic (tiron), a 
catechol-based metal sequestering agent with ROS scavenging properties, has been described 
as being able to permeabilize the mitochondrial membrane and thereby be localized in the 
mitochondrion from the cytoplasm (Krishna et al., 1992; McArdle et al., 2005; Tulah and Birch-
Machin, 2013). Such antioxidants have been shown to protect against UVA- and H2O2-induced 
mitochondrial DNA damage. Despite the attractive nature of these protective strategies, such 
‘conventional’ antioxidants which scavenge mitochondrial ROS will have only a limited 
protective effect in the skin particularly at the level of mitochondria. This is because they cannot 
properly address the presence of excess LI in the organelle which is the major contributor to the 
generation of highly reactive ROS and oxidative damage especially upon exposure of cells to 
strong oxidising agents such as UVA (Reelfs et al., 2010). 
The challenge of countering the effects of the combination of UVA and iron-catalysed excess 
ROS formation in the mitochondria highlights a clear need for the development of mitochondria-
targeted iron chelating agents in order to adjust and remove the excess harmful pool of 
mitochondrial LI. Limited exposure of cultured fibroblasts and keratinocytes to the strong iron 
chelator desferrioxamine (DFO) protects skin cells against biologically relevant UVA doses. 
Nevertheless, despite being a strong iron chelator, DFO is not an adequate choice for use in 
skin photoprotection via topical application, due to its hydrophilicity and elevated molecular 
weight (MW) (Reelfs et al., 2010). Although bidentate iron chelators (e.g. catechols and 
hydroxypyridinones) possess adequate lipophilicity and MW, they have a weak iron scavenging 
ability at low iron concentrations. This is a major drawback in their use for skin photoprotection 
via topical application (Liu and Hider, 2002). We therefore decided to opt for hexadentate 
analogues as these compounds would have similar structures to siderophores (Hider and Zhou, 
2005) and would have a high iron scavenging ability despite possessing elevated MW. 
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A powerful mitochondria-targeted hexadentate tricatechol-based iron chelator was synthesized 
and evaluated in cells in culture for its protective effects against UVA-induced iron-catalyzed 
oxidative damage and cell death. We demonstrate that this compound is capable of protecting 
mitochondria and thereby skin cells from the deleterious effects of UVA component of sunlight. 
 
 
RESULTS 
Compound design and synthesis  
We have recently demonstrated the successful use of mitochondria-targeted ‘SS-peptides’ for 
the delivery of iron-specific sensors to the mitochondria (Abbate et al., 2015a and b). We 
therefore chose the same approach to target an iron chelator to the mitochondria. 
The catechol-based hexadentate iron chelator described in this study possesses the following 
properties (i) high affinity for iron (pFe >25) and (ii) the iron-complexes do not redox cycle at 
physiological pH. These properties render compound 2 suitable for skin photoprotection. 
Table S1 and Figure 1 document the structures of the compounds investigated in this study. 
Compound 1 is a simple SS-type mitochondria-targeted peptide which we designed to form the 
leading mitochondrial address signal to which we have linked an hexadentate chelator to form 
compound 2. Compound 3 is a fluorescent version of compound 2 possessing a dansyl 
fluorophore (Dns) which renders it possible to follow its subcellular localization by fluorescence 
microscopy. We have previously shown that the Dns fluorophore (absorption and emission 
maxima: 330 and 546 nm, respectively) is a suitable choice as it does not alter the biological 
function of the chelator-peptide (Abbate et al., 2015a and b). Finally, in compound 4, hemi-
methylation of one of the catechol groups renders this compound less efficient at binding iron 
than its counterpart compound 2. Table S2 provides some relevant physico-chemical properties 
of the compounds and Figure S1 their HPLC profiles. Although the clogD7.4 value for compound 
2 is low (-2.05, Table S2), it is 3 orders of magnitude larger than that of the parent peptide 1 (-
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5.39). Peptide 1 is able to penetrate membranes with relative ease (Zhao et al., 2004) probably 
by the formation of lipid-peptide complexes. We anticipate that compound 2 will have similar 
properties especially as it is markedly less hydrophilic than peptide 1. 
 
Subcellular localisation of the chelator-peptide in human primary skin fibroblasts 
Using fluorescence microscopy, we first investigated the subcellular localization of compound 3 
in primary skin fibroblast FEK4 cells. Cells were incubated with compound 3 and co-stained with 
a fluorescent marker specific for mitochondria, lysosomes or endoplasmic reticulum (ER) as 
described in “Cell biology” section in Supplementary Information file. Colocalization of 
compound 3 to specific organelles was evaluated qualitatively by (i) the occurrence of 
composite fluorescent yellow signal generated by the co-occurrence of both green and red 
fluorescent signals above a threshold level (Figure 2) and (ii) intensity profile comparison 
(Figure S2). Quantitative evaluation of the extent of colocalization was performed as described 
in Supplementary Information file. The results of both qualitative and quantitative analyses 
revealed that compound 3 was able to penetrate cells and accumulate preferentially into 
mitochondria (Figure 2, panels a-d). This tropism for mitochondria was specific, as we could not 
observe any colocalization with lysosome/endosome (Figure 2, panels e-h) or ER compartments 
(Figure 2, panels i-l). The same subcellular pattern of localization was observed for compound 3 
using FCP7 (primary skin fibroblasts from another donor) which we have previously studied in 
our laboratory (Zhong et al., 2004). Representative pictures and intensity profiles are presented 
in Figure S5a. 
 
UVA-induced cell death is prevented by the tricatechol peptide 
In order to highlight the photoprotective role of iron chelation strategy in exposure to solar UV, 
we chose to use a broad-spectrum UVA lamp (320-400nm) rather than the whole UV spectrum 
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as a light source. This has the notable advantage to allow to demonstrate the UVA-specificity of 
the biological effects observed. 
To evaluate the photoprotective capability of compound 2 against UVA-induced cell death, we 
chose the UVA dose of 500 kJ/m2 which is equivalent  to 140 min uninterrupted sun exposure at 
sea level (Pourzand et al., 1999). This is a high but still physiological dose, typically met in 
recreational sun exposure during a sunny holiday. FEK4 cells were pre-incubated (or not) with 
compound 2 and UVA-irradiated.  
Figure 3a shows phase contrast microscopy images of the morphological changes occurring 
following various treatments, 24 h post-irradiation. UVA-irradiated cells exhibited significant 
swelling that is typical of necrosis (Figure 3a). The morphology of cells treated with compound 2 
alone (cpd 2) or followed by UVA irradiation (cpd 2 + UVA) was indistinguishable from that of 
untreated control cells (no UVA). When cells were pre-treated with a complex of compound 2 
saturated with iron prior to irradiation, the damage incurred appeared similar to that observed 
with UVA alone. Taken together, these results demonstrate that the mitochondria-targeted 
compound 2 is capable of protecting the cells against UVA-induced damage. This 
unprecedented level of protection appears to be due to the strong iron-scavenging activity of 
compound 2, since it is abrogated upon complexation of compound 2 with iron (cpd 2-Fe). 
We also scored the percentages of live, apoptotic and necrotic cells by flow cytometry using 
dual staining with Annexin V-FLUOS/propidium iodide (PI) 24 h after UVA treatment (see 
Supplementary Information). Representative Annexin V versus PI scatter plots are shown in 
Figure 3b and the percentages of live cells are plotted in Figure 3c. Untreated control, cpd 2-
treated and cpd 2-Fe–treated cells all exhibited similar high levels of live populations (ca 90%, 
Figure 3b). UVA induced predominantly necrotic cell death (ca 40%, Figure 3b), consistent with 
the morphologic changes observed microscopically. Furthermore, the percentage of cells 
undergoing apoptosis in UVA-irradiated samples remained low (ca 14%, Figure 3b). 50 µM 
compound 2 afforded full protection against UVA-induced cell death as seen by restoration of 
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percentage of live cells to control levels (Figures 3b and 3c). Photoprotection was 
concentration-dependent and could be observed with as low as 5 µM compound 2 (Figure S4). 
Compound 4, a form of compound 2 less able to bind iron, afforded half of the protection 
provided by the latter, while compound 1 (with no iron-binding activity) had no effect on cell 
survival when incubated with cells prior to UVA irradiation (Figure 3c). Finally, in line with the 
morphological observations made in Figure 3a, pre-treatment of cells with the “inactive” (iron-
complexed) chelator-peptide failed to protect them against UVA-induced necrotic cell death 
(Figures 3b and 3c). The complex per se did not generate any significant toxicity. The protective 
effects observed with compound 2 were reproducible with the Dns-labeled version compound 3, 
indicating that the Dns fluorophore does not alter the biological function of the chelator-peptide, 
as previously observed (Abbate et al., 2015a). In FCP7 fibroblasts, compound 2 afforded full 
protection against UVA radiation in an iron-dependent fashion (Figure S5b), confirming the 
results obtained with FEK4 cells.  
 
   
The tricatechol peptide prevents the loss of mitochondria membrane potential associated 
with UVA irradiation 
Loss of mitochondrial membrane potential is an early consequence of UVA radiation-mediated 
oxidative damage to mitochondrial membrane (Zhong et al., 2004; Pourzand and Tyrrell, 1999). 
Since compound 2 localizes specifically to the mitochondria, we sought to identify if its 
mechanism of protection involved the prevention of mitochondrial membrane depolarisation. For 
this purpose, FEK4 cells were pre-incubated (or not) with compound 2 and irradiated with 500 
kJ/m2 UVA. They were then incubated with the mitochondria-specific red fluorescent cationic 
dye tetramethylrhodamine methyl ester (TMRM) and analysed by flow cytometry 2 h and 24 h 
after UVA. A decrease in TMRM fluorescence is indicative of mitochondrial membrane 
depolarisation.  
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The results (Figures 4a and 4b) revealed that UVA induced a dramatic drop in TMRM 
fluorescence already at the 2 h time point. This drop was similar to the depolarisation caused by 
the mitochondrial membrane uncoupling compound FCCP (data not shown). However, pre-
treatment with compound 2 provided a significant protection at that time point. While at 24 h 
time point, there was a partial but noticeable recovery of TMRM fluorescence in cells treated 
with UVA, full recovery of membrane potential could be observed in compound 2-treated cells. 
In contrast, compound 4 was not able to prevent significantly the UVA-induced decrease in 
mitochondrial membrane potential at 2 h post-irradiation, in line with its lower iron-binding 
capability. Nevertheless, it afforded an intermediate level of protection at the 24 h time-point, 
although less marked than that observed with compound 2. Taken together, these results show 
a direct link between the UVA-induced mitochondrial membrane damage and necrotic cell 
death, both of which could be fully prevented by pre-treatment with the mitochondrial iron 
chelator compound 2. Similar results were obtained using FCP7 cells (Figure S5c), albeit 
revealing a higher sensitivity to UVA-induced mitochondrial damage when compared to FEK4 
cells. 
 
The protective effect of mitochondria-targeted chelator compound 2 on ATP depletion 
associated with UVA-mediated necrosis 
We investigated if the protection of the mitochondrial membrane potential afforded by 
compound 2 upon UVA irradiation correlated with a protection against ATP depletion. The 
measurement of the intracellular level of ATP 4 h (data not shown) and 24 h after UVA 
irradiation (Figure 4c) showed that UVA irradiation depleted up to 80% of ATP levels compared 
to unirradiated control cells, as previously observed (Zhong et al., 2004). Pre-treatment of cells 
with compound 2 significantly recovered the ATP levels to 60% of the control level at both time 
points (Figure 4c and data not shown). This level of protection against ATP depletion appears to 
be sufficient to prevent necrotic cell death induced by UVA (Figure 3). Furthermore, the 
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protection afforded by compound 2 against UVA-induced ATP depletion appeared to be iron-
dependent since its complexation with iron abolished its protective effect. In a similar fashion to 
FEK4 cells, compound 2 diminished UVA-induced ATP depletion (Figure S5d) in FCP7 cells. 
 
 
DISCUSSION 
We have shown that the mitochondria-targeted compound 2 provides an unprecedented 
protection against oxidative damage and cell death induced by a high but environmentally 
relevant dose of UVA in primary skin fibroblast cells. The abrogation of cell death by these 
chelator-peptides is entirely iron-dependent, since their iron saturation abolished their 
photoprotective effect. Furthermore partial impairment of the iron binding capability of one of the 
catechol moieties in compound 4, significantly reduced its photoprotective ability (Figure 3c).  
We chose an ‘SS-like  peptide’ for the effective delivery of our hexadentate iron chelator to the 
organelle, due to the known mitochondrial selectivity of this family of peptides (Zhao et al., 2003; 
Szeto, 2008; Szeto and Schiller, 2011; Abbate et al., 2015a and b). These peptides as well as 
some recently described cationic and lipophilic peptides (Horton et al., 2008; Yousif et al., 2009) 
have been used successfully as carriers of functional molecules (including antioxidants or 
drugs) to the mitochondria (Zhao et al., 2004;  Zhao et al., 2005;  Pereira and Kelley, 2011). 
These aromatic-cationic peptides, unlike Mito Q, are not taken up due to mitochondrial 
membrane potential (∆ψm) as they are reported to be concentrated in depolarized mitochondria 
(Doughan and Dikalov, 2007; Cerrato et al., 2015). 
It is essential that the iron chelating peptides we describe herein do not interfere with the normal 
cellular ferrokinetic pathways, otherwise serious toxic side-effects could be anticipated. 
Hexadentate catechols are highly selective for iron(III), the oxidation state of iron that 
accumulates in situations of both iron overload and the uncontrolled lysis of lysosomes. 
Whereas the cytosol contains a labile iron pool of iron(II), the lysosomes possess a high content 
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of ferritin, which in turn contains iron(III). Although hexadentate catechols can autoxidise iron(II), 
the rates of this reaction are extremely slow at iron concentrations of 1-2 µM which are typically 
found in mammalian cell cytosol (Hider and Kong, 2013). Thus we do not anticipate appreciable 
interference with the cytosolic iron pool or mitochondrial iron pool, which is also dominated by 
iron(II), under normal physiological conditions (Ma et al., 2015). A similar situation occurs with 
deferiprone, a hydroxypyridin-4-one, which has been used for over twenty years in clinical 
practice for the treatment of iron overload. Like hexadentate catechols, deferiprone is highly 
selective for iron(III). Although it facilitates the autoxidation of iron(II), it does so at an extremely 
low rate at low µM concentrations (Devanur et al., 2008). 
The role of LI in UVA-induced oxidative damage and necrotic cell death has long been 
established (Morliere et al., 1991; Pourzand and Tyrrell, 1999; Kvam et al., 2000; Dissemond et 
al., 2003; Zhong et al., 2004). Earlier studies focussed more on oxidant-mediated destabilisation 
of lysosomes (Pourzand et al., 1999; Yu et al., 2003; Basu-Modak et al., 2006; Fakih et al., 
2008). However subsequent studies recognised mitochondria as the principal destination of LI in 
cells and therefore a primary site of pro-oxidant generation rendering these organelles 
particularly susceptible to oxidative damage. Indeed high levels of chelatable LI have been 
detected by several groups in the mitochondria of cultured cells using various probes (Rauen et 
al., 2007; Glickstein et al., 2005; Petrat et al., 2002). Additional studies by us have established 
that the oxidant-induced destabilisation of mitochondrial membrane resulting from intra-
mitochondrial Fenton reactions is one of the early cellular events occurring after UVA irradiation 
of skin cells (Zhong et al., 2004; Yiakouvaki et al., 2006). This provokes a loss of mitochondrial 
membrane potential and ATP depletion leading irreversibly to necrotic cell death (Zou et al., 
1999; Green and Reed, 1998) which can be prevented by iron chelators such as salicylaldehyde 
isonicotinoyl hydrazone (SIH). This is due to the capability of these compounds to not only 
deplete the cytosolic LIP but also to access and sequester the loosely available LI in both 
lysosomal and mitochondrial compartments (Yiakouvaki et al., 2006; Pelle et al., 2011; Simunek 
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et al., 2005). An inevitable consequence of prolonged non-targeted chelating activity of such 
chelators is unwanted cytotoxicity (Reelfs et al., 2010; Yu et al., 2006). Compound 2, which is 
entirely localized to the mitochondria is expected not to display such undesired side effects. 
Indeed, time-course studies performed in our laboratory comparing compound 2 and SIH show 
that unlike SIH, compound 2 does not exhibit any cytotoxicity at the highest tested concentration 
of 100 µM up to 48 h exposure (see Figure S6). Our results in the two cell lines FEK4 and FCP7 
clearly show that compound 2 is fully protective against UVA-induced necrotic cell death despite 
showing a partial protection against ATP depletion. This phenomenon has already been 
observed in an unrelated study with Jurkat T cells treated with H2O2 showing that iron chelators 
were effective at protecting cells against necrotic cell death yet not being fully effective in 
protecting against ATP depletion. This suggests that oxidant-induced ATP depletion is only 
partially iron-dependent. A plausible iron-independent mechanism would involve oxidant-
induced damage to mitochondrial respiratory chain proteins. Because both UVA and H2O2 are 
glutathione-depleting agents (Lautier et al., 1992; Al-Qenaie et al., 2014), protein oxidative 
damage would be exacerbated under these conditions. Further studies are necessary to unravel 
these iron-independent mechanisms but this is out of the scope of this study. Nevertheless, it 
appears that following UVA or H2O2 treatment, cells may only need to reach a threshold level of 
ATP production to be able to fully evade necrotic cell death. This is strengthened by the 
observation that partial replenishment of ATP by glucose supplementation can rescue skin 
fibroblasts from UVA-induced necrotic cell death (Zhong et al., 2004). 
The importance of mitochondrial LI in oxidative injuries has also been demonstrated in a series 
of genetic disorders with defective cellular iron utilization (i.e. trafficking and incorporation into 
proteins) resulting in toxic increase in iron concentrations in mitochondria of excitable cells often 
leaving the cytosol iron-depleted (Kakhlon et al., 2010; Richardson et al., 2010). For example 
cultured fibroblasts from Friedreich’s ataxia (FRDA) patients that contain high mitochondrial iron 
level have been shown to be highly sensitive to iron stress and significantly more sensitive to 
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H2O2-induced cell death than fibroblasts from healthy individuals (Wong et al., 1999; Lim et al., 
2008). The highly specific and mitochondria-targeted iron chelator designed in this study should 
therefore be beneficial for the therapy of mitochondrial iron-related oxidative injuries and 
pathological conditions such as FRDA. While recently a series of mitochondria-targeted 
antioxidants have been proposed for the therapy of mitochondria-related pathologies (Jauslin et 
al., 2003; Jauslin et al., 2007; Zhao et al., 2004; Zhao et al., 2005), to our knowledge a highly 
specific mitochondria-targeted iron chelator such as the one introduced here has not yet been 
reported. 
A variety of iron chelator molecules have been patented as part of sunscreen formulations 
(Reelfs et al., 2010). While their mild iron chelating properties provide protection against UVB-
induced damage, studies from this laboratory and others have demonstrated that these 
compounds are not effective against UVA-induced iron damage (Reelfs et al., 2010; Aroun et 
al., 2012; Creighton-Gutteridge and Tyrrell, 2002). For efficient protection against UVA-induced 
iron damage of skin, strong chelators are required. However these are incompatible with 
prolonged systemic administration due to toxic effects caused by iron starvation of healthy cells. 
The mitochondria-targeted chelator-peptide compound 2 provides a solution to this problem and 
thus can address the current unmet need in the skin care/sunscreen field for potent sunscreen 
ingredients that are targeted specifically to the principal site of the damage (i.e. mitochondria) in 
the skin cells and are highly effective UVA photoprotectant. It can argued that compound 2 may 
have an effect on iron-sulfur cluster and/or heme synthesis. Although these important issues are 
out of the scope of this manuscript, we plan to address them in the near future. 
In daily life, skin cells are clearly not exposed exclusively to the UVA waveband but to the entire 
solar spectrum which also includes UVB. We are introducing the strategy of iron chelation as 
photoprotectant with the intent to incorporate the chelating molecule as an ingredient to a 
sunscreen formulation designed to protect against both UVA and UVB components of sunlight. 
Current filters provide ‘passive’ protection by absorbing and reflecting harmful UV rays from the 
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skin. Manufacturers have adopted an alternative strategy of adding antioxidants such as 
vitamins C and E, to their sunscreen products which offers ‘active’ protection by boosting the 
body’s natural antioxidant reserve to quench any ROS generated from UVA that has passed the 
UV filters. Despite the attractive nature of this photoprotection strategy, numerous studies in this 
field have demonstrated that ‘conventional’ antioxidants which scavenge OS (e.g. vitamins C 
and E,) have only a very modest protective effect (Reelfs et al., 2010). However studies from 
our laboratory and others have demonstrated that iron, and in particular mitochondrial iron, 
plays a major role in the oxidative damage caused by UVA (Aroun et al., 2012). Within this 
context, we propose that our mitochondria-targeted iron chelator be added as an essential UVA 
photoprotectant to sunscreen formulations.  
 
 
 
MATERIALS AND METHODS 
Chelator and Peptide Synthesis 
See Supplementary Information for protocols and characterization information. 
 
Reagents 
For cell cultivation, all reagents used were cell culture-grade and purchased from Life 
Technologies (Paisley, Scotland), except foetal calf serum (FCS), which was from Life 
Technologies Ltd (Paisley, UK) and phosphate buffered saline (PBS) from Oxoid Ltd 
(Basingstoke, UK). TMRM and the organelle-specific markers MitoTracker® Deep Red FM, 
Lyso Tracker® Deep Red and ER TrackerTM Red were purchased from Invitrogen (Paisley, 
Scotland). Annexin V-FLUOS was from Roche (Welwyn Garden City, UK). All other reagents 
were from Sigma-Aldrich (Gillingham, UK). 
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Cell culture 
The human primary fibroblasts FEK4 and FCP7 were a kind gift from Prof. Tyrrell’s laboratory 
and were grown as described previously (Abbate et al., 2015a). The foreskin fibroblast cultures 
were initiated in Prof. Tyrrell’s laboratory, Switzerland, from tissue samples obtained in full 
compliance with ethical regulations and legislation in force at the time and respecting complete 
donor confidentiality. Patient consent for experiments was not required because under Swiss 
laws in force at the time, human material left over from surgery was considered as discarded 
material. These cells have been isolated from foreskin biopsies at passage 0. From that, sub-
cultured and frozen stocks between passage 1 and 12 were available for the present study. 
 
Treatments and peptide delivery 
The (chelator)-peptides were prepared as 100 mM stock solutions in DMSO. They were diluted 
to the desired final concentration (50 µM unless specified) and added to cells overnight as 
described previously (Abbate et al., 2015a and b).  
 
UVA irradiation 
Irradiations were performed in PBS at approximately 25 °C using a broad spectrum Sellas 4 kW 
UVA lamp (Sellas, Germany), as described previously (Pourzand et al., 1999).  
 
Flow cytometry and Live cell microscopy 
All flow cytometry- and live cell microscopy-based protocols are described in Supplementary 
Information file. 
 
ATP measurement 
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ATP production by cells following various treatments was monitored with a luminometer (Turner 
Designs Model TD-20/20) 24 h after UVA, using the ViaLight™ plus kit (Lonza Biologics plc, 
Slough, U.K.) as described previously (Al-Qenaei et al., 2014).  
 
Iron complexation 
Iron:ligand complexes were prepared by mixing equimolar amounts of iron(III) as FeCl3• 6H2O 
and the hexadentate-peptide molecule. The complex was allowed to form for 1 h at room 
temperature prior to incubation with the cells overnight at 37 °C at a final concentration of 50 
µM. 
 
Statistical methods 
Results are expressed as the mean +/- SD. Significant differences (P < 0.05) were determined 
by either paired or unpaired t-test after one-way analysis of variance. 
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FIGURE LEGENDS 
 
Figure 1: Structures of compounds 1-4. 
The structures of the compounds investigated are depicted with their ionized functions at pH 
7.4. Iron-binding functions are indicated in blue. The dansyl (Dns) fluorophore is indicated in 
red. 
 
Figure 2. Microscopy images of subcellular localization studies of the DNS-labelled 
peptide-chelator H-Hbl-Hbl-Hbl-r-F-DAP(Dns)-NH2 (compound 3). 
Representative microscopy images are shown, of cells stained with compound 3 in combination 
with markers for mitochondrial (a-d), lysosomal (e-h) and ER (i-l) compartments. Fluorescence 
data were collected and analysed as described in Materials and Methods. Green (b, f, j) and red 
(c, g, k) fluorescence data were merged together (d, h, l) to identify co-localization in yellow. 
The phase contrast images (a, e, i) corresponding to the fluorescence data are also shown. 
Scale bar = 10 µm. 
 
Figure 3. Compound 2 protects FEK4 cells from UVA-induced cell death. 
Cells were treated with compound 2 (cpd 2) alone or as a complex with iron (cpd 2-Fe) or UVA 
or combinations thereof. a. Bright-field images were captured 24 h post-treatment. Swelling 
(arrows in insert) is indicative of cell death by necrosis and is visible following UVA treatment 
alone or in combination with cpd 2-Fe. Scale bar = 50 µm. b. Cells treated as described above 
were processed for flow cytometry analysis as described in Materials and Methods. Dot plots of 
a representative experiment are shown. Live cells are defined as Annexin V-negative/PI-
negative (lower left-hand quadrant). c. Bar chart of flow cytometry results, expressed as means 
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+/- SD of percentage live cells from 3-5 experiments. * Significantly different (p<0.05) from UVA 
alone. † Significantly different (p<0.05) from cpd 2+UVA. 
 
Figure 4. Compound 2 significantly reduces UVA-induced damage to mitochondria 
membrane. 
a. Representative fluorescence intensity profiles of samples stained with TMRM at 2 h and 24 h 
post-UVA irradiation as described in Materials and Methods. b. Bar chart of the results of TMRM 
staining experiments. Fluorescence median intensities (MFIs) collected over the region 
delineated in panel a as P2 are expressed as percentage of untreated control. * Significantly 
different (p<0.05) from corresponding UVA-treated sample. † Significantly different (p<0.05) 
from corresponding cpd 2+UVA-treated sample. c. FEK4 cells were pre-treated with either 
compound 2 alone or as a complex with iron, prior to UVA irradiation and ATP production was 
measured as described in Materials and Methods. Results are expressed as percentage of 
untreated control. * Significantly different (p<0.05) from UVA alone sample.  
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